The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Takeda Completes Acquisition of Multilab, Mid-Sized Brazilian Pharm Company
July 5, 2012
- Zonegran Approved for Monotherapy in Europe: Eisai
July 5, 2012
- Nippon Kayaku Considers Promotional Measures for Biosimilars, Vascular Embolization Medical Devices
July 5, 2012
- AZ to Promote Symbicort, SMART Therapy Targeting GPs, Specialists
July 5, 2012
- Ono to Start PI Trial for Anticancer Vaccine Licensed from OncoTherapy
July 5, 2012
- Japan Becomes World No. 2 Vaccine Market Pushed by HPV Vaccines
July 4, 2012
- Sanofi, Hisamitsu Set Up Joint Venture with Sanofi Chief as President and Chairman
July 4, 2012
- AnGes MG to License Exclusive US Marketing Rights for Collategene to MTPC
July 4, 2012
- 230 MSs of Mediceo Begin to Work as ARs for Sawai
July 4, 2012
- COPD Treatment Oxis Approved, to Be Marketed by Meiji Seika Pharma: AZ
July 4, 2012
- Taisho Makes Tokuhon Wholly Owned Subsidiary; Expanding Business in Topical, Adhesive Agents
July 4, 2012
- Over 60% of Meiji Seika Pharma’s Generics Have Top 3 Market Share: GM Umeki
July 3, 2012
- Nippon Kayaku in Final Preparatory Stage for NK105 PIII Trials: Managing Director Suzuki
July 3, 2012
- Japan’s 5th DPP-4 Inhibitor Tenelia Approved: MTPC
July 3, 2012
- Otsuka, Kyowa Kirin Announce Strategic Alliance in Fields of Diabetes, Oncology
July 2, 2012
- Astellas Receives Approval for Prostate Cancer Treatment Gonax
July 2, 2012
- Toyama Chemical, Eisai Receive Approval for Anti-Rheumatic Treatment, to Market under 2 Brands
July 2, 2012
- Takeda Initiates International PIII Trial of Velcade Successor
July 2, 2012
- Mirabegron Approved in the US: Astellas
July 2, 2012
- Anti-Obesity Agent Belviq Approved in US, to Be Launched in Jan. 2013: Eisai
July 2, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…